What "Research Use Only" Really Means on a Peptide Vial

The short answer

"Research use only" is a phrase borrowed from a narrow corner of FDA regulation and repurposed as a sales disclaimer. On a vial of BPC-157 Low or retatrutide sold to anyone with a card, it does not make the product legal, does not mean it was made or tested to any standard, and does not stop FDA or federal prosecutors from treating it as an unapproved drug. What it mainly does is move responsibility from the seller to the buyer.

That is not just our reading. It is how FDA's regulations define a product's purpose, how FDA wrote to five online peptide sellers in August 2026, and how federal prosecutors have described the same disclaimer in court for more than a decade. This guide walks through each, then covers what the label means for the person holding the vial. Everything here is current as of September 30, 2026, and it is general information, not legal advice.

Where the phrase actually comes from

The words have a real regulatory home, and it is not injectable peptides. They come from the rules for in vitro diagnostics: test kits, reagents and instruments used on samples outside the body. Under 21 CFR 809.10, a diagnostic product still in the laboratory research phase, and not represented as an effective diagnostic, must carry the statement "For Research Use Only. Not for use in diagnostic procedures."¹ The label tells a laboratory that the kit is unproven, so its results cannot guide anyone's care.

Even there, FDA has said the label is only as good as the conduct behind it. When it finalised its guidance on research-use diagnostics in 2013, the agency described it as a reminder that such labeling must match the manufacturer's actual intended use of the product.² A company that sells a "research" kit to clinics for diagnosis is selling a diagnostic, whatever the box says.

Drugs have their own, much stricter version. A new drug may be shipped without FDA approval for tests in vitro or in laboratory animals, under 21 CFR 312.160, if it carries a caution that it is for investigational use in laboratory research animals or in vitro tests and is not for use in humans.³ The same rule requires the shipper to use due diligence to make sure the recipient regularly conducts such research and that the drug will actually be used that way, to keep records of each expert it ships to for two years, and to recover unused supplies. FDA can end the arrangement if the drug is used for anything other than bona fide scientific investigation.³ A website that ships to whoever ticks a box saying they are a researcher meets none of these conditions. The exemption exists for laboratories, and it assumes the seller knows who they are.

Why the label does not decide what the product is

Under the Food, Drug, and Cosmetic Act, whether something is a drug turns on what it is intended for. FDA's regulation on intended use, amended in 2021, defines that as the objective intent of the people responsible for the product's labeling, and says it can be shown by their own statements, by the design or composition of the product, or by the circumstances in which it is sold, including advertising and oral or written statements by the seller.⁴ A disclaimer is one piece of that evidence, and it is easily outweighed.

The August 2026 warning letters show how FDA weighs it. The agency reviewed the websites of five online peptide sellers and found semaglutide High, tirzepatide, retatrutide, tesamorelin, SS-31 and PT-141 among the products, several under grey-market nicknames. It told each seller that these were new drugs without approved applications, so selling them across state lines violated the Act.⁵ The disclaimers did not help, because the rest of each site spoke louder: product pages describing weight loss, blood sugar control and sexual function; a linked PubChem page on semaglutide's cardiovascular benefits; bacteriostatic water sold beside the vials, itself listed as an unapproved drug in at least three letters; and, on two sites, a peptide calculator that FDA described as the means to prepare an injectable drug for a person.⁵ FDA has made the same point about GLP-1 drugs in general, warning companies that sell semaglutide, tirzepatide and related drugs falsely labeled "for research purposes" or "not for human consumption."⁶

FDA reads the whole shop, not the sign on the door. A seller can write "research use only" on every page and still be selling drugs for people to inject, and when the dosing charts, reconstitution supplies and before-and-after claims sit next to the disclaimer, the disclaimer is the least persuasive thing on the page.

How prosecutors have treated it

Warning letters are FDA's opinion. Criminal cases are where the disclaimer has been tested under oath, and federal prosecutors have described it the same way for years.

In 2014, two Charlotte men pleaded guilty to selling misbranded drugs through two peptide companies, Osta-Gain and later Spectrum Peptides. Their websites said all products were for research purposes only. According to the plea, the products were in fact sold for human use to bodybuilders, along with pipettes and dosing information; the sites ran Black Friday and Christmas sales and free T-shirt promotions; and when a newspaper article named the first company, the owners closed it and reopened under a new name, selling the same products. Sales came to about $800,000.⁷

In 2016, a federal judge in Maryland sentenced the owner of Precision Peptides and DNA Peptides to six months of home confinement and three years of probation, and ordered forfeiture of more than $2.1 million. His sites carried "research/laboratory use only" disclaimers and made customers certify that the products were not for human ingestion. Prosecutors called the disclaimers a ruse to avoid FDA scrutiny: he advertised in bodybuilding magazines, paid professional bodybuilders to vouch for results, and published dosing and injection-site advice. The products included GHRP-2 Medium, GHRP-6, ipamorelin Medium and Melanotan II Low.⁸

In 2021, a Birmingham man was sentenced to 30 months in prison and ordered to forfeit $900,000 over a peptide called PNC-27. He had assured his Chinese supplier that the peptide was solely for laboratory research, described his business as a research effort and called himself a research director, then made suppositories in his kitchen and a rented warehouse and sold them as a cancer treatment.⁹ And in October 2024, the operator of a site selling SARMs and unapproved copies of semaglutide pleaded guilty in Vermont to selling unapproved drugs with intent to defraud. His pages said "research purposes only" and "not for human consumption" beside claims about what the products would do to the body; he kept selling after an FDA warning letter and made three sales to an undercover account.¹⁰

Nobody in these cases was convicted for writing a disclaimer; they were convicted for selling drugs meant for people. The disclaimer appears in the court record as evidence that they knew.

What the label does not tell you about the vial

A research-use label carries no quality promise. An approved drug is made under current good manufacturing practice and released only after testing for identity, strength and, for injectables, sterility and bacterial endotoxin. A vial labeled for research sits outside that system, so any quality claim on the page is the seller's own.

When researchers placed test orders with illegal online pharmacies selling semaglutide, the vials that arrived held 29% to 39% more semaglutide than their labels stated, measured purity was 7.7% to 14.4% against the 99% printed on them, and every vial contained bacterial endotoxin.¹¹ In a separate study, nuclear magnetic resonance analysis of custom-synthesised research peptides found an undeclared ingredient, mannitol, making up 20% to 43% of the material.¹² Neither finding would be visible from the label, and a certificate of analysis supplied by the same seller cannot settle it on its own; our guide to judging quality claims and the COA decoder explain what a certificate can and cannot show.

What it means if you buy

The law is aimed mostly at sellers. The federal violations in the cases above are about introducing unapproved or misbranded drugs into interstate commerce. That is why FDA writes to companies and prosecutors charge distributors. It does not make buying safe or approved; it means the "research use only" label protects the seller's position, not yours.

Importing is different. FDA says that in most circumstances it is illegal for individuals to import drugs for personal use when those drugs are not approved in the US.¹³ The agency may use discretion for small personal shipments, generally up to a three-month supply, but its stated criteria include a serious condition without effective treatment available at home, no promotion of the product to people in the US, a written statement that the product is for personal use, and either the name of the US-licensed doctor responsible for the treatment or evidence that treatment began abroad.¹³ A peptide marketed online to US customers struggles on several of those points. Shipments can also be stopped at the border: FDA's import alert for unapproved new drugs promoted in the US lets its staff detain listed products without examining them, and its red list includes PT-141, melanotan, GHRP-2, GHRP-6 and ipamorelin from named foreign sellers.¹⁴ In the PT-141 entry, FDA's evidence was the seller's own social media page, where the company's president answered a customer's dosing question.¹⁴

A doctor cannot fix the status of the vial. A clinician can prescribe approved drugs and, within strict limits, compounded ones. For compounding, FDA's advisory committee reviewed BPC-157, TB-500 Low and other peptides in July 2026, and our regulatory tracker follows what FDA decides.¹⁵ A research vial is neither, so there is no label, no dosing information and no one accountable for its contents.

Athletes have no defence in the label. The World Anti-Doping Agency lists BPC-157 under S0, non-approved substances, and "research use only" on the vial changes nothing about a positive test.¹⁶ For the country-by-country picture, including the UK, EU, Canada and Australia, see our guide to peptide legality.

Reading a research-use-only page

The details FDA and prosecutors cited are the same ones a buyer can see. A site selling to researchers has little reason to publish dosing charts, injection-site diagrams, reconstitution calculators, "stacks" for fat loss or muscle, customer before-and-after stories, or bundles of bacteriostatic water and syringes. When those sit beside the disclaimer, the site is telling you what it expects the product to be used for, and so is telling FDA.

None of that tells you whether the vial is what it claims. That takes independent testing of the vial in your hand, which our verification guide covers. It also cannot tell you whether the compound is safe or effective in people; for most research peptides, including BPC-157, that has barely been studied at all, which is the subject of each compound's encyclopedia entry.

Frequently asked questions

Is it legal to buy research peptides in the US?

Selling them for human use is not: FDA treats them as unapproved new drugs, and the cases on this page were brought against sellers. Buying is not approved either; importing unapproved drugs for personal use is illegal in most circumstances, and FDA can detain listed peptides at the border. This is general information, not legal advice.

Does "research use only" mean a peptide is safe for human use?

No. It means the seller disclaims human use. The product is made outside the controls that apply to medicines, and test purchases have found vials far from their labels in purity and content, with bacterial endotoxin present.

Why do sellers use the label if it does not protect them?

It is a legal posture: it lets a seller say the buyer, not the seller, decided to use the product on a person. FDA and courts look past it to the rest of the website, the marketing and the supplies sold alongside.

Is there any legitimate research-use-only product?

Yes. Diagnostic reagents in development carry the phrase by regulation, and new drugs can be shipped to laboratories for animal or in vitro research under a rule that requires the shipper to verify the recipient and keep records. Neither covers a vial sold to the public.

Can a doctor prescribe a research peptide?

A doctor can prescribe approved drugs and, within limits, compounded drugs from substances FDA allows. A vial sold for research is neither, so there is no labeling, no dosing information and no accountable manufacturer.

Related on Grey Peptides

• Are peptides legal? Country guide
• How to judge quality claims
• COA decoder
• Regulatory tracker

Sources

1. Code of Federal Regulations. 21 CFR 809.10(c)(2)(i): labeling of in vitro diagnostic products in the laboratory research phase of development, which must bear the statement "For Research Use Only. Not for use in diagnostic procedures." eCFR, current as of September 1, 2026; read September 30, 2026.
2. U.S. Food and Drug Administration. Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: guidance for industry and FDA staff; notice of availability. Federal Register, November 25, 2013 (2013-28084). Federal Register
3. Code of Federal Regulations. 21 CFR 312.160: drugs for investigational use in laboratory research animals or in vitro tests (the required caution statement, due diligence on the consignee, shipment records kept for 2 years, termination of authorization, return of unused supplies). eCFR, current as of September 1, 2026; read September 30, 2026.
4. U.S. Food and Drug Administration. Regulations Regarding "Intended Uses": final rule amending 21 CFR 201.128 and 801.4. Federal Register, 86 FR 41383, August 2, 2021; effective September 1, 2021. Federal Register
5. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Warning letters to five online peptide sellers dated August 24, 2026 and posted September 1, 2026 (NuScience Peptides LLC, 733652, linked; Royal Peptides LLC; TXP Innovations LLC; Peak Performance Peptides; Peptide Partners LLC). Read September 30, 2026. FDA
6. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss: warnings to companies selling semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labelled "for research purposes" or "not for human consumption"; buy only from state-licensed pharmacies. Content current as of September 1, 2026; read September 30, 2026. FDA
7. U.S. Attorney's Office, Western District of North Carolina. Two Charlotte men plead guilty to selling misbranded drugs (Osta-Gain and Spectrum Peptides). Press release, November 13, 2014. Read September 30, 2026.
8. U.S. Attorney's Office, District of Maryland. Owner of bodybuilding drug companies sentenced for selling misbranded drugs (Precision Peptides and DNA Peptides). Press release, May 9, 2016. Read September 30, 2026.
9. U.S. Attorney's Office, Northern District of Alabama. Birmingham man sentenced for making unapproved drug products (PNC-27). Press release, May 26, 2021. Read September 30, 2026.
10. U.S. Attorney's Office, District of Vermont (republished by FDA's Office of Criminal Investigations). California man pleads guilty to selling unapproved drugs with intent to defraud over the internet (Warrior Labz SARMs). October 17, 2024. Read September 30, 2026. FDA
11. Ashraf, A. R. et al. (2024). Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. J Med Internet Res, 26, e65440. PMID: 39509151 · doi:10.2196/65440
12. Choules, M. P. et al. (2020). NMR reveals an undeclared constituent in custom synthetic peptides. J Pharm Biomed Anal, 178, 112915. PMID: 31671336 · doi:10.1016/j.jpba.2019.112915
13. U.S. Food and Drug Administration. Personal Importation (content current as of August 18, 2025). Read September 30, 2026. FDA
14. U.S. Food and Drug Administration. Import Alert 66-41: Detention Without Physical Examination of Unapproved New Drugs Promoted in the U.S. (red-list entries including PT-141, melanotan, GHRP-2, GHRP-6 and ipamorelin). Published September 29, 2026; read September 30, 2026.
15. US Food and Drug Administration (2026). Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026: briefing documents for BPC-157, TB-500, epitalon and four other bulk drug substances. FDA
16. World Anti-Doping Agency. The 2026 Prohibited List, in force January 1, 2026: BPC-157 named under S0 (non-approved substances); the 2027 list, published August 2026, keeps it there. Read September 27, 2026. WADA

This guide explains what a label means under US rules as of September 30, 2026. It is general information, not legal or medical advice, and it is not an endorsement of buying unapproved compounds.